TYRA · Tyra Biosciences, Inc.
$20.22
+0.25 (+1.25%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$1.19B
Shares
59.68M
Volume · Oct 9
95.2K
Avg daily vol (3M)
856.21K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.97
Open$20.12
Day$19.50–20.17
52W close$13.52–39.61
Avg vol 30d1.2M
Short int9.9M · 16.6% float · 5.7d
Short vol82%
Last earningsSep 9, 2026
DataSep 2021–Oct 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Feb 10, 2027
Est · unconfirmed
· in 18 wks
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$148.56M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-9.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$73.83M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+10.8%
Year over year · more shares
Price change (1Y)
+52.5%
Trailing year
Short interest
16.6%
Latest settlement · 5.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−34%
below
Price vs 50-day avg
−20%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−44%
trailing
YTD return
−24%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $30 — 200d above 50d
Institutional flow
Distributing
3 of 170 funds reported for Sep 30 · net -38 sh shares
Insider flow
Accumulating
Net +$20.0K over 90 days · 0% sells
Short interest
Rising
16.55% of float · ▲ +4.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
170 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
−33%
Y/Y
Free cash flow
$-95.3M
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
7.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−34%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $25 › 200d $30 — 200d above 50d
Institutional flow
Distributing
3 of 170 funds reported for Sep 30 · net -38 sh shares
Insider flow
Accumulating
Net +$20.0K over 90 days · 0% sells
Short interest
Rising
16.55% of float · ▲ +4.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
170 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $20 · 25%
Range high $40
vs 200-day avg -34%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TYRA
this stock
Tyra Biosciences, Inc.
|
$1.19B | -24.0% | — | — | 16.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TYRA | -5.0% | -15.2% | -43.8% | -8.7% | -24.0% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -6.3% | -17.3% | -52.8% | -10.2% | -37.5% |